Edition:
United States

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

91.60DKK
17 Aug 2018
Change (% chg)

kr.1.40 (+1.55%)
Prev Close
kr.90.20
Open
kr.91.10
Day's High
kr.92.80
Day's Low
kr.90.80
Volume
65,916
Avg. Vol
71,163
52-wk High
kr.127.00
52-wk Low
kr.78.50

Chart for

About

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and... (more)

Overall

Beta: 1.02
Market Cap(Mil.): kr.2,816.82
Shares Outstanding(Mil.): 30.75
Dividend: --
Yield (%): --

Financials

  ZELA.CO Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -12.17 -- --
ROI: -95.66 2.89 12.63
ROE: -150.59 1.65 14.82

BRIEF-Zealand Pharma Announces Interim Report For The First Quarter Of 2018

* ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST QUARTER OF 2018 Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Zealand Q1 Net Sales Of Soliqua 100/33 And Lyxumia/Adlyxin At EUR 14.5 Mln

* REG-ZEALAND ANNOUNCES NET SALES OF SOLIQUA® 100/33 AND LYXUMIA®/ADLYXIN® FOR THE FIRST QUARTER OF 2018

Apr 27 2018

BRIEF-Zealand Announces Successful End-Of-Phase 2 Meeting With FDA On Glepaglutide For Short Bowel Syndrome

* ZEALAND ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH FDA ON GLEPAGLUTIDE FOR SHORT BOWEL SYNDROME

Apr 26 2018

BRIEF-Zealand And Roche Diabetes Care Enter Phase 3 Study Collaboration For Treatment Of Congenital Hyperinsulinism With Dasiglucagon

April 11 Zealand Pharma A/S - Co Is Responsible For Conducting Phase 3 Trials, While Roche Diabetes Care Provides Its Accu :

Apr 11 2018

BRIEF-Zealand Pharma Enters Collaboration Agreement With Roche Diabetes Care

* HAS ENTERED A COLLABORATION AGREEMENT WITH ROCHE DIABETES CARE

Apr 11 2018

BRIEF-Zealand Pharma: Positive Results From First Phase 3 Trial For Treatment Of Severe Hypoglycemia

* REG-ZEALAND PHARMA'S FIRST PHASE 3 TRIAL WITH DASIGLUCAGON FOR TREATMENT OF SEVERE HYPOGLYCEMIA SUCCESSFULLY MEETS ITS PRIMARY OBJECTIVE

Mar 20 2018

BRIEF-Zealand Pharma FY Net Loss At DKK 272.3 Million​

* FY 2017 REVENUE DKK ‍​ 139.8 MILLION VERSUS DKK 234.8 MILLION YEAR AGO

Mar 07 2018

BRIEF-Zealand Pharma And Uniquest Collaborate To Develop Novel Drug Candidates

* REG-ZEALAND PHARMA AND UNIQUEST COLLABORATE TO DEVELOP NOVEL DRUG CANDIDATES FOR GASTROINTESTINAL DISEASES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Feb 20 2018

Earnings vs. Estimates